The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1272
October 22, 2007
View Complete Issue         Table of Contents 2019 
Ambrisentan (Letairis) for Pulmonary Arterial Hypertension
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ambrisentan (Letairis) for Pulmonary Arterial Hypertension
October 22, 2007 (Issue: 1272)
Ambrisentan (Letairis - Gilead), a selective endothelin type A (ETA) receptor antagonist, has been approved by the FDA for treatment of symptomatic patients (WHO class II or III) with pulmonary arterial hypertension (PAH).
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ambrisentan (Letairis) for Pulmonary Arterial Hypertension
Article code: 1272b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.